Gamma Aminobutyric Acid Receptor Market - Market Size, Sustainable Insights and Growth Report 2024-2031

Gamma-Aminobutyric Acid (GABA) Receptor Market Size, Share, Industry, Forecast and outlook (2024-2031)

<h2>Gamma-Aminobutyric Acid (GABA) Receptor Market is segmented By Medications(Benzodiazepines, Barbiturates, Vigabatrin, Propofol, Flumazenil, Baclofen, Gabapentin, Zolpidem, Others), By Type (GABAA, GABAB), By Application (Alzheimer's Disease, Attention Deficit Hyperactivity Disorder, Psychiatric Disorders, General anesthesia, Neuropathic pain, Muscle relaxant, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share Outlook, and Opportunity Analysis,&nbsp;2023-2030</h2><blockquote>Gamma-Aminobutyric Acid (GABA) Receptor Market&nbsp;expected to reach at a&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://www.datamintelligence.com/download-sample/gamma-aminobutyric-acid-receptor-market">CAGR of 4.5%</a>&nbsp; during the forecast period (2023-2030).&nbsp;</blockquote>Gamma-Aminobutyric acid (GABA) is an important inhibitory neurotransmitter found in the central nervous system of mammals. The neurotransmitter reduces the activity of neurons to which it binds, thus is used to control anxiety or fear when neurons are overexcited. GABA receptors are protein molecules that respond to neurotransmitter GABA.Gamma-Aminobutyric Acid (GABA) Receptor Market<figure class="table"><table border="1" cellpadding="1" cellspacing="1"><tbody><tr><td>Metrics</td><td>Details</td></tr><tr><td>Market&nbsp;CAGR</td><td>4.5%</td></tr><tr><td>Segments Covered</td><td>By Medications, By Type, By Application, and By Region</td></tr><tr><td>Report Insights Covered</td><td>Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.</td></tr><tr><td>Fastest Growing Region</td><td>Asia Pacific</td></tr><tr><td>Largest Market Share&nbsp;</td><td>North America</td></tr></tbody></table></figure>To Get a Free Sample&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://www.datamintelligence.com/download-sample/gamma-aminobutyric-acid-receptor-market">Click here</a><h3>Gamma-Aminobutyric Acid (GABA) Receptor Market Dynamics&nbsp;</h3>The global gamma-aminobutyric acid (GABA) receptor market growth is driven by the rise in incidences of neurological disorders and increase in the aging population; increased funding by government and private organizations across emerging economies for the treatment of neurological disorders is expected to provide growth opportunities for market growth.The rise in incidences of neurological disorders coupled with the introduction of novel drugs is expected to drive market growth.The increasing prevalence of epilepsy is the major driving factor of the market. For instance, According to World Health Organization (WHO), around 50 million people worldwide have epilepsy. The average incidence of epilepsy each year in the U. S is estimated at 150,000 or 48 for every 100,000 people. Also found that in the United States, the number of males and females with epilepsy was 1,477,323 and 1,331,276, respectively, in 2017. Benzodiazepines (BZDs) are essential agents in the management of epilepsy. They are the first choice of drugs for status epilepticus and seizures associated with post-anoxic insult. They are also frequently used to treat febrile, acute repetitive and alcohol withdrawal seizures. Clinical advantages of these drugs include they bind to the GABA-A receptor, increasing the calming effect, rapid onset of action, high efficacy rates and minimal toxicity. Benzodiazepines are used in various clinical situations because they have a broad spectrum of clinical activity and can be administered via several routes. For instance, In January 2020, the US FDA approved Neurelis, Inc drug Valtoco (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in people with epilepsy six years of age and older.Side effects associated with the GABA receptor binding drugs are likely to hamper market growth.The most common side effects of GABA include dizziness, anxiety, drowsiness, dry mouth, balance problems, constipation, blurred vision, itchiness, irritation, stomach pain, memory problems, increased appetite, joint and muscle pain.<h3>Gamma-Aminobutyric Acid (GABA) Receptor Market- Industry Analysis</h3><h3>COVID-19 Impact Analysis</h3>COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. The World Health Organization (WHO) declared the COVID-19 pandemic on March 11, 2020. This pandemic has disrupted growth in many economies across various domains. Management of anxiety, delirium, and agitation cannot be neglected in coronavirus disease (COVID-19). Antipsychotics are usually used for the pharmacological management of delirium, and confusion and behavioral disturbances. The concurrent use of treatments for COVID-19 and antipsychotics had eventual drug-drug interactions, which had a short-term negative impact on the market.<h3>Gamma-Aminobutyric Acid (GABA) Receptor Market Segment Analysis</h3>The diazepam segment is expected to hold the largest share in this market segment.Diazepam is likely to be the largest segment during the forecast period due to the new route of administration, strategic collaboration between companies for the development &amp; commercialization of diazepam, and lower prescription cost for major diazepam factors attributed to the higher growth of the diazepam segment.&nbsp;For instance, Valtoco a Neurelis, Inc product&nbsp;is a proprietary formulation of diazepam incorporating the unique combination of a vitamin E-based solution and Intravail absorption enhancement to obtain outstanding absorption, tolerability, and reliability in a nasal formulation and; it is delivered via a nasal formulation in a spray, being developed to manage children and adult patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity, also known as cluster seizures. The exact mechanism of action for diazepam is not fully understood. Still, it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor.<h3>Gamma-Aminobutyric Acid (GABA) Receptor Market Geographical Analysis</h3>North America region holds the largest market share of the global gamma-aminobutyric acid (GABA) receptor market.&nbsp;North America is expected to dominate the global benzodiazepine drugs market due to more FDA approvals in that region. For instance, In February 2020, the United States Food and Drug Administration supported Merck for its Belsomra drug in treating insomnia in patients with mild-to-moderate Alzheimer's disease. An article published by the National Center for Biotechnology Information, U.S. Library of Medicine in February 2018 stated that 50,000 to 150,000 people in the U.S. suffer from status epilepticus, with mortality estimated at less than 3% in children, but up to 30% in adults. For instance, Aquestive Therapeutics collaborated with Syneos Health, Covance, in 2020 completed Phase 3 trial of safety and tolerability study of chronic intermittent use of Diazepam Buccal Soluble Film (DBSF) in Pediatric, Adolescent and Adult Subjects with Epilepsy. An increase in the development of mental healthcare services and rising awareness towards anxiety disorders are responsible for the rise in the diagnosis of a generalized anxiety disorder (GAD).<h3>Gamma-Aminobutyric Acid (GABA) Receptor Market Competitive Landscape</h3>Gamma-Aminobutyric acid (GABA) receptor market is highly competitive with the presence of local as well as international companies. The key players contributing to the market's growth include Merck Kagan, Bausch Health US LLC, Pfizer Inc, Lundbeck, Sanofi-Aventis U.S. LLC, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd, LGM PHARMA.&nbsp;Global Gamma-Aminobutyric Acid (GABA) Receptor Market – Key Companies to WatchPfizer Inc&nbsp;Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also consists of a research and development (R&amp;D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.Product Portfolio: XANAX (ALPRAZOLAM)- XANAX is a benzodiazepine indicated for the acute treatment of generalized anxiety disorder in adults.<h3 style="background-color:#eeeeee;border:1px solid #cccccc;padding:5px 10px;">Frequently Asked Questions</h3>What is the Projected CAGR value of the Gamma-Aminobutyric Acid (GABA) Receptor Market?Gamma-Aminobutyric Acid (GABA) Receptor Market is expected to grow at a&nbsp;CAGR of 4.5%&nbsp;during the forecasting period 2022-2029.Which region controlled the global market during 2022-2029?North America&nbsp;region Controls&nbsp;the&nbsp;Gamma-Aminobutyric Acid (GABA) Receptor Market&nbsp;during 2022-2029Which is the fastest growing region in the Gamma-Aminobutyric Acid (GABA) Receptor Market?Among all regions,&nbsp;Asia Pacific&nbsp;is the fastest growing market share during the forecast period&nbsp;<h3 style="background-color:#eeeeee;border:1px solid #cccccc;padding:5px 10px;">Trending Topic's</h3><a target="_blank" rel="noopener noreferrer" href="https://www.datamintelligence.com/research-report/gamma-delta-t-cell-cancer-therapy-market">Gamma Delta T Cell Cancer Therapy Market</a><a target="_blank" rel="noopener noreferrer" href="https://www.datamintelligence.com/research-report/inflammatory-bowel-disease-market">Inflammatory Bowel Disease Market</a>

<h2 style="background-color:#eeeeee;border:1px solid #cccccc;padding:5px 10px;">Table of Contents</h2><ol><li><h3 style="color:#1f3863;font-style:normal;">Global Gamma-Aminobutyric Acid (GABA) Receptor Methodology and Scope</h3><ol><li>Research Methodology</li><li>Research Objective and Scope of the Report</li></ol></li><li><h3 style="color:#1f3863;font-style:normal;">Market Definition and Overview</h3></li><li><h3 style="color:#1f3863;font-style:normal;">Executive Summary</h3><ol><li>Market Snippet by Type</li><li>Market Snippet by Medications</li><li>Market Snippet by Indication</li><li>Market Snippet by Region </li></ol></li><li>Market Dynamics<ol><li>Market Impacting Factors<ol><li>Drivers<ol><li>The rise in incidences of neurological disorders coupled with the introduction of novel drugs</li></ol></li><li>Restraints:<ol><li>Side effects associated with the GABA receptor binding drugs</li></ol></li><li>Opportunity</li><li>Impact Analysis</li></ol></li></ol></li><li><h3 style="color:#1f3863;font-style:normal;">Industry Analysis&nbsp;</h3><ol><li>Porter's Five Forces Analysis </li><li>Supply Chain Analysis</li><li>Pipeline Analysis</li><li>Pricing Analysis</li><li>Regulatory Analysis</li></ol></li><li>COVID-19 Analysis<ol><li>Analysis of Covid-19 on the Market<ol><li>Before COVID-19 Market Scenario</li><li>Present COVID-19 Market Scenario</li><li>After COVID-19 or Future Scenario</li></ol></li><li>Pricing Dynamics Amid Covid-19</li><li>Demand-Supply Spectrum</li><li>Government Initiatives Related to the Market During Pandemic</li><li>Manufacturers Strategic Initiatives</li><li>Conclusion&nbsp;</li></ol></li><li><h3 style="color:#1f3863;font-style:normal;">By Medications</h3><ol><li>Introduction<ol><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications Segment.</li><li>Market Attractiveness Index, By medications Segment</li></ol></li><li>Benzodiazepines*<ol><li>Introduction</li><li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li><li>Lorazepam (Ativan)</li><li>Midazolam (Versed)</li><li>Alprazolam (Xanax)</li><li>Diazepam (Valium)</li></ol></li><li>Barbiturates<ol><li>Methohexital (Brevital)</li><li>Pentobarbital (Nembutal)</li><li>Amobarbital (Amytal)</li><li>Primidone (Mysoline)</li></ol></li><li>Vigabatrin</li><li>Propofol</li><li>Flumazenil</li><li>Baclofen</li><li>Gabapentin</li><li>Zolpidem</li><li>Others</li></ol></li><li><h3 style="color:#1f3863;font-style:normal;">By Type</h3><ol><li>Introduction<ol><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li><li>Market Attractiveness Index, By Type</li></ol></li><li>GABAA*<ol><li>Introduction</li><li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li></ol></li><li>GABAB</li></ol></li><li><h3 style="color:#1f3863;font-style:normal;">By Application</h3><ol><li>Introduction<ol><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li><li>Market Attractiveness Index, By Application</li></ol></li><li> Alzheimer's Disease*<ol><li>Introduction</li><li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li></ol></li><li>Attention Deficit Hyperactivity Disorder</li><li>Psychiatric Disorders</li><li>General anesthesia</li><li>Neuropathic pain</li><li>Muscle relaxant</li><li>Other</li></ol></li><li><h3 style="color:#1f3863;font-style:normal;">By Region</h3><ol><li>Introduction<ol><li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region</li><li>Market Attractiveness Index, By Region</li></ol></li><li>North America<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country<ol><li>The U.S.</li><li>Canada</li><li>Mexico</li></ol></li></ol></li><li>Europe<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country<ol><li>Germany</li><li>The U.K.</li><li>France</li><li>Italy</li><li>Spain</li><li>Rest of Europe</li></ol></li></ol></li><li>South America<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country<ol><li>Brazil</li><li>Argentina</li><li>Rest of South America</li></ol></li></ol></li><li>Asia Pacific<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country<ol><li>China</li><li>India</li><li>Japan</li><li>Australia</li><li>Rest of Asia Pacific</li></ol></li></ol></li><li>The Middle East and Africa<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li></ol></li></ol></li><li><h3 style="color:#1f3863;font-style:normal;">Competitive Landscape</h3><ol><li>Competitive Scenario</li><li>Key Developments and Strategies </li><li>Company Share Analysis</li><li>Product Benchmarking</li><li>Key Companies to Watch</li><li>Company with disruptive technology</li></ol></li><li><h3 style="color:#1f3863;font-style:normal;">Company Profiles</h3><ol><li>Pfizer Inc*<ol><li>Company Overview</li><li>Product Portfolio and Description</li><li>Key Highlights</li><li>Financial Overview</li></ol></li><li>Merck KGaA</li><li>Bausch Health US LLC</li><li>Lundbeck</li><li>Sanofi-Aventis U.S. LLC</li><li>Amneal Pharmaceuticals LLC</li><li>Sun Pharmaceutical Industries Ltd</li><li>LGM PHARMA (*LIST NOT EXHAUSTIVE)</li></ol></li><li><h3 style="color:#1f3863;font-style:normal;">DataM&nbsp;Intelligence</h3><ol><li>Appendix</li><li>About Us and Services</li><li>Contact Us</li></ol></li></ol>

<h2 style="background-color:#eeeeee;border:1px solid #cccccc;padding:5px 10px;">List of Tables &amp; Figures</h2>List of TablesTable 1 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Medications, 2021, 2025 &amp; 2029 ($ Million)Table 2 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Type, 2021, 2025 &amp; 2029 ($ Million)Table 3 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Application, 2021, 2025 &amp; 2029 ($ Million)Table 4 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)Table 5 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Medications, 2021, 2025 &amp; 2029 ($ Million)Table 6 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Medications, 2019-2029 ($ Million)Table 7Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Type, 2021, 2025 &amp; 2029 ($ Million)Table 8 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Type, 2019-2029 ($ Million)Table 9 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Application, 2021, 2025 &amp; 2029 ($ Million)Table 10 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Application, 2019-2029 ($ Million)Table 11 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)Table 12 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Region, 2019-2029 ($ Million)Table 13 North America Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Medications, 2019-2029 ($ Million)Table 14 North America Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Type, 2019-2029 ($ Million)Table 15 North America Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Application, 2019-2029 ($ Million)Table 16 North America Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Country, 2019-2029 ($ Million)Table 17 South America Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Medications, 2019-2029 ($ Million)Table 18 South America Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Type, 2019-2029 ($ Million)Table 19 South America Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Application, 2019-2029 ($ Million)Table 20 South America Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Country, 2019-2029 ($ Million)Table 21 Europe Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Medications, 2019-2029 ($ Million)Table 22 Europe Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Type, 2019-2029 ($ Million)Table 23 Europe Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Application, 2019-2029 ($ Million)Table 24 Europe Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Country, 2019-2029 ($ Million)Table 25 Asia-Pacific Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Medications, 2019-2029 ($ Million)Table 26 Asia-Pacific Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Type, 2019-2029 ($ Million)Table 27 Asia-Pacific Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Application, 2019-2029 ($ Million)Table 28 Asia-Pacific Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Country, 2019-2029 ($ Million)Table 29 Middle East &amp; Africa Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Medications, 2019-2029 ($ Million)Table 30 Middle East &amp; Africa Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Type, 2019-2029 ($ Million)Table 31 Middle East &amp; Africa Gamma-Aminobutyric Acid (GABA) Receptor Market Value, By Application, 2019-2029 ($ Million)Table 32 Merck KGaA: OverviewTable 33 Merck KGaA: Product PortfolioTable 34 Merck KGaA: Key DevelopmentsTable 35 Bausch Health US LLC: OverviewTable 36 Bausch Health US LLC: Product PortfolioTable 37 Bausch Health US LLC: Key DevelopmentsTable 38 Lundbeck: OverviewTable 39 Lundbeck: Product PortfolioTable 40 Lundbeck: Key DevelopmentsTable 41 Sanofi-Aventis U.S. LLC: OverviewTable 42 Sanofi-Aventis U.S. LLC: Product PortfolioTable 43 Sanofi-Aventis U.S. LLC: Key DevelopmentsTable 44 Amneal Pharmaceuticals LLC: OverviewTable 45 Amneal Pharmaceuticals LLC: Product PortfolioTable 46 Amneal Pharmaceuticals LLC: Key DevelopmentsTable 47 Sun Pharmaceutical Industries Ltd: OverviewTable 48 Sun Pharmaceutical Industries Ltd: Product PortfolioTable 49 Sun Pharmaceutical Industries Ltd: Key DevelopmentsTable 50 LGM PHARMA: OverviewTable 51 LGM PHARMA: Product PortfolioTable 52 LGM PHARMA: Key DevelopmentsTable 53 Pfizer Inc: OverviewTable 54 Pfizer Inc: Product PortfolioTable 55 Pfizer Inc: Key DevelopmentsList of FiguresFigure 1 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Medications, 2021 &amp; 2029 (%)Figure 2 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Type, 2021 &amp; 2029 (%)Figure 3 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Application, 2021 &amp; 2029 (%)Figure 4 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Region, 2021 &amp; 2029 (%)Figure 5 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 6 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Y-o-Y Growth, By Medications, 2021-2029 (%)Figure 7 Benzodiazepines: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 8 Barbiturates: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 9 Vigabatrin: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 10 Propofol: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 11 Flumazenil: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 12 Baclofen: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 13 Gabapentin: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 14 Others: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 15 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Y-o-Y Growth, By Type, 2021-2029 (%)Figure 16 GABAA: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 17 GABAB: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 18 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Y-o-Y Growth, By Application, 2021-2029 (%)Figure 19 attention deficit hyperactivity disorder: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 20 Psychiatric Disorders: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 21 Alzheimer's Disease: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 22 General anesthesia: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 23 Neuropathic pain: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 24 Muscle relaxant: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 25 Others: Global Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 26 Global Gamma-Aminobutyric Acid (GABA) Receptor Market Y-o-Y Growth, By Region, 2021-2029 (%)Figure 27 North America Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 28 North America Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Medications, 2021 &amp; 2029 (%)Figure 29 North America Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Type, 2021 &amp; 2029 (%)Figure 30 North America Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Application, 2021 &amp; 2029 (%)Figure 31 North America Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Country, 2021 &amp; 2029 (%)Figure 32 South America Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 33 South America Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Medications, 2021 &amp; 2029 (%)Figure 34 South America Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Type, 2021 &amp; 2029 (%)Figure 35 South America Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Application, 2021 &amp; 2029 (%)Figure 36 South America Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Country, 2021 &amp; 2029 (%)Figure 37 Europe Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 38 Europe Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Medications, 2021 &amp; 2029 (%)Figure 39 Europe Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Type, 2021 &amp; 2029 (%)Figure 40 Europe Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Application, 2021 &amp; 2029 (%)Figure 41 Europe Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Country, 2021 &amp; 2029 (%)Figure 42 Asia-Pacific Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 43 Asia-Pacific Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Medications, 2021 &amp; 2029 (%)Figure 44 Asia-Pacific Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Type, 2021 &amp; 2029 (%)Figure 45 Asia-Pacific Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Application, 2021 &amp; 2029 (%)Figure 46 Asia-Pacific Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Country, 2021 &amp; 2029 (%)Figure 47 Middle East &amp; Africa Gamma-Aminobutyric Acid (GABA) Receptor Market Value, 2019-2029 ($ Million)Figure 48 Middle East &amp; Africa Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Medications, 2021 &amp; 2029 (%)Figure 49 Middle East &amp; Africa Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Type, 2021 &amp; 2029 (%)Figure 50 Middle East &amp; Africa Gamma-Aminobutyric Acid (GABA) Receptor Market Share, By Application, 2021 &amp; 2029 (%)Figure 51 Merck KGaA: FinancialsFigure 52 Bausch Health US LLC: FinancialsFigure 53 Lundbeck: FinancialsFigure 54 Sanofi-Aventis U.S. LLC: FinancialsFigure 55 Amneal Pharmaceuticals LLC: FinancialsFigure 56 Sun Pharmaceutical Industries Ltd: FinancialsFigure 57 LGM PHARMA: FinancialsFigure 58 Pfizer Inc: Financials&nbsp;